{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T18:22:35Z","timestamp":1785435755639,"version":"3.56.0"},"reference-count":32,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Science and Technology Council","award":["NSTC 114-2221-E-003-037"],"award-info":[{"award-number":["NSTC 114-2221-E-003-037"]}]},{"name":"National Science and Technology Council","award":["NSTC 113-2221-E-155-032"],"award-info":[{"award-number":["NSTC 113-2221-E-155-032"]}]},{"award":["NSTC 114-2221-E-003-037"],"award-info":[{"award-number":["NSTC 114-2221-E-003-037"]}],"id":[{"id":"https:\/\/ror.org\/00wnb9798","id-type":"ROR","asserted-by":"publisher"}]},{"award":["NSTC 113-2221-E-155-032"],"award-info":[{"award-number":["NSTC 113-2221-E-155-032"]}],"id":[{"id":"https:\/\/ror.org\/00wnb9798","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Neovascular age-related macular degeneration (nAMD), including typical nAMD (tAMD) and polypoidal choroidal vasculopathy (PCV), is a leading cause of visual impairment. This study investigated the real-world short-term outcomes of faricimab, a bispecific antibody targeting Ang-2 and VEGF-A, in patients with treatment-na\u00efve or -refractory nAMD. Materials and Methods: This retrospective study analyzed treatment-na\u00efve or -refractory nAMD eyes receiving one, two, or three monthly intravitreal faricimab injections. Primary outcomes were changes in best-corrected visual acuity (BCVA) and central foveal thickness (CFT) one month after the last injection. Secondary outcomes included the dry macula rate (absence of subretinal and intraretinal fluid) and subgroup comparisons between tAMD and PCV. Results: After a single injection, both treatment-na\u00efve (n = 76) and -refractory (n = 44) eyes showed significant CFT reduction (p &lt; 0.0001) but no significant BCVA improvement (p &gt; 0.05). Dry macula was achieved in 63.2% of treatment-na\u00efve and 71.4% of treatment-refractory eyes. In 38 treatment-na\u00efve eyes receiving three injections, both CFT and BCVA significantly improved from baseline (p &lt; 0.001 and p = 0.02, respectively), with a 94.7% dry macula rate. Subgroup analysis of those receiving three injections revealed that PCV eyes exhibited significant visual improvement, whereas tAMD eyes did not. No serious systemic or ocular adverse events were observed over the short-term follow-up period. Conclusions: Intravitreal faricimab is effective for both treatment-na\u00efve and -refractory nAMD in the short term. While anatomical improvements were comparable between subtypes, the PCV subgroup showed a trend toward greater visual improvement in this small cohort; however, this may be influenced by the significantly younger age of PCV patients. These findings are exploratory and require validation in larger, age-matched prospective studies.<\/jats:p>","DOI":"10.3390\/medicina62050863","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T13:32:21Z","timestamp":1777555941000},"page":"863","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Short-Term Outcomes of Intravitreal Faricimab for Treatment-Na\u00efve and -Refractory Neovascular Age-Related Macular Degeneration: A Real-World Study"],"prefix":"10.3390","volume":"62","author":[{"given":"Huai-Lung","family":"Chang","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Far Eastern Memorial Hospital, New Taipei City 22060, Taiwan"},{"name":"Department of Medicine, National Taiwan University, Taipei City 106216, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-Uei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Far Eastern Memorial Hospital, New Taipei City 22060, Taiwan"},{"name":"Department of Medicine, National Yang Ming Chiao Tung University, Taipei City 112304, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Lun","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Far Eastern Memorial Hospital, New Taipei City 22060, Taiwan"},{"name":"Department of Electrical Engineering, Yuan Ze University, Taoyuan City 320315, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Yao","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Far Eastern Memorial Hospital, New Taipei City 22060, Taiwan"},{"name":"Department of Medicine, National Taiwan University, Taipei City 106216, Taiwan"},{"name":"Department of Electrical Engineering, Yuan Ze University, Taoyuan City 320315, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Ting","family":"Ho","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Far Eastern Memorial Hospital, New Taipei City 22060, Taiwan"},{"name":"Department of Medicine, National Taiwan University, Taipei City 106216, Taiwan"},{"name":"Department of Medicine, National Yang Ming Chiao Tung University, Taipei City 112304, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yung-Ray","family":"Hsu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Far Eastern Memorial Hospital, New Taipei City 22060, Taiwan"},{"name":"Department of Medicine, National Taiwan University, Taipei City 106216, Taiwan"},{"name":"Department of Electrical Engineering, Yuan Ze University, Taoyuan City 320315, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6534-7246","authenticated-orcid":false,"given":"Fang-Ting","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Far Eastern Memorial Hospital, New Taipei City 22060, Taiwan"},{"name":"Department of Medicine, National Taiwan University, Taipei City 106216, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Ju","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Far Eastern Memorial Hospital, New Taipei City 22060, Taiwan"},{"name":"Department of Medicine, National Taiwan University, Taipei City 106216, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8373-2271","authenticated-orcid":false,"given":"Cheng-Hung (Dixson)","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Electrical Engineering, Yuan Ze University, Taoyuan City 320315, Taiwan"},{"name":"Department of Electrical Engineering, National Taiwan Normal University, Taipei City 106308, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3157-3613","authenticated-orcid":false,"given":"Jia-Kang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Far Eastern Memorial Hospital, New Taipei City 22060, Taiwan"},{"name":"Department of Medicine, National Taiwan University, Taipei City 106216, Taiwan"},{"name":"Department of Medicine, National Yang Ming Chiao Tung University, Taipei City 112304, Taiwan"},{"name":"Department of Electrical Engineering, Yuan Ze University, Taoyuan City 320315, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.ophtha.2009.10.007","article-title":"The prevalence of age-related macular degeneration in Asians: A systematic review and meta-analysis","volume":"117","author":"Kawasaki","year":"2010","journal-title":"Ophthalmology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2147\/OPTH.S385827","article-title":"Polypoidal Choroidal Vasculopathy: An Update on Diagnosis and Treatment","volume":"17","author":"Sen","year":"2023","journal-title":"Clin. Ophthalmol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1136\/bjophthalmol-2013-303513","article-title":"Non-responders to treatment with antagonists of vascular endothelial growth factor in age-related macular degeneration","volume":"97","author":"Krebs","year":"2013","journal-title":"Br. J. Ophthalmol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.15252\/emmm.201505889","article-title":"Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases","volume":"8","author":"Regula","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): Two randomised, double-masked, phase 3, non-inferiority trials","volume":"399","author":"Heier","year":"2022","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1007\/s00417-023-06071-8","article-title":"Efficacy, durability, and safety of faricimab in patients from Asian countries with neovascular age-related macular degeneration: 1-Year subgroup analysis of the TENAYA and LUCERNE trials","volume":"261","author":"Takahashi","year":"2023","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1038\/s41433-023-02553-5","article-title":"The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: The TRUCKEE study\u20146 month results","volume":"37","author":"Khanani","year":"2023","journal-title":"Eye"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1007\/s00417-023-06116-y","article-title":"Short-term outcomes of intravitreal faricimab for treatment-naive neovascular age-related macular degeneration","volume":"261","author":"Matsumoto","year":"2023","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"8747","DOI":"10.1038\/s41598-023-35759-4","article-title":"Three-month outcomes of faricimab loading therapy for wet age-related macular degeneration in Japan","volume":"13","author":"Mukai","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2147\/OPTH.S448507","article-title":"Short-Term Outcomes of 3 Monthly intravitreal Faricimab On Different Subtypes of Neovascular Age-Related Macular Degeneration","volume":"18","author":"Tanaka","year":"2024","journal-title":"Clin. Ophthalmol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00417-023-06241-8","article-title":"Comparison of functional and morphologic changes between brolucizumab and faricimab in neovascular age-related macular degeneration","volume":"262","author":"Yanagi","year":"2024","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1007\/s00417-024-06582-y","article-title":"Three-month outcomes of treatment with faricimab or aflibercept for neovascular age-related macular degeneration: A propensity score matching study in a Japanese population","volume":"262","author":"Fukuda","year":"2024","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/s41598-024-82746-4","article-title":"Outcomes and predictive factors for fluid resolution following three loading injections of faricimab for treatment-naive neovascular age-related macular degeneration","volume":"15","author":"Han","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"21128","DOI":"10.1038\/s41598-023-48190-6","article-title":"Therapeutic effects of faricimab on aflibercept-refractory age-related macular degeneration","volume":"13","author":"Tamiya","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_17","first-page":"e40100","article-title":"Faricimab Effectively Resolves Intraretinal Fluid and Preserves Vision in Refractory, Recalcitrant, and Nonresponsive Neovascular Age-Related Macular Degeneration","volume":"15","author":"Cheng","year":"2023","journal-title":"Cureus"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Ng, B., Kolli, H., Ajith Kumar, N., Azzopardi, M., Logeswaran, A., Buensalido, J., Mushtaq, B., Chavan, R., and Chong, Y.J. (2024). Real-World Data on Faricimab Switching in Treatment-Refractory Neovascular Age-Related Macular Degeneration. Life, 14.","DOI":"10.3390\/life14020193"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Machida, A., Oishi, A., Ikeda, J., Kurihara, J., Yoneda, A., Tsuiki, E., Hirata, Y., Murakami, R., and Kitaoka, T. (2024). Factors Associated with Success of Switching to Faricimab for Neovascular Age-Related Macular Degeneration Refractory to Intravitreal Aflibercept. Life, 14.","DOI":"10.20944\/preprints202401.0743.v1"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1007\/s00417-024-06485-y","article-title":"Short-term outcomes of intravitreal faricimab for refractory neovascular age-related macular degeneration","volume":"262","author":"Aljundi","year":"2024","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00417-023-06222-x","article-title":"Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration","volume":"262","author":"Kataoka","year":"2024","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1159\/000540833","article-title":"The Short-Term Efficacy and Safety of Faricimab in Refractory Neovascular Age-Related Macular Degeneration: The Real-World Experience in Taiwan","volume":"247","author":"Chi","year":"2024","journal-title":"Ophthalmologica"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s40123-025-01163-6","article-title":"Early Anatomical and Functional Outcomes of Faricimab in Recalcitrant Neovascular Age-Related Macular Degeneration: A Retrospective Real-World Study in an East-Asian Population","volume":"14","author":"Lai","year":"2025","journal-title":"Ophthalmol. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1007\/s00417-025-06930-6","article-title":"One-year outcomes of three-monthly and four-monthly loading regimens of faricimab for treatment-naive neovascular age-related macular degeneration","volume":"263","author":"Doi","year":"2025","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"100906","DOI":"10.1016\/j.preteyeres.2020.100906","article-title":"Incomplete response to Anti-VEGF therapy in neovascular AMD: Exploring disease mechanisms and therapeutic opportunities","volume":"82","author":"Mettu","year":"2021","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"104496","DOI":"10.1016\/j.drudis.2025.104496","article-title":"Therapeutic strategies targeting ocular vasculopathies: Current advances and emerging challenges","volume":"30","author":"Ronco","year":"2025","journal-title":"Drug Discov. Today"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1167\/iovs.64.5.28","article-title":"Mechanisms of Acquired Resistance to Anti-VEGF Therapy for Neovascular Eye Diseases","volume":"64","author":"Sharma","year":"2023","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"11389","DOI":"10.1038\/s41598-019-47738-9","article-title":"Dynamic changes in choroidal conditions during anti-vascular endothelial growth factor therapy in polypoidal choroidal vasculopathy","volume":"9","author":"Nagai","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/s41433-023-02764-w","article-title":"Macular neovascularization and polypoidal choroidal vasculopathy: Phenotypic variations, pathogenic mechanisms and implications in management","volume":"38","author":"Cheung","year":"2024","journal-title":"Eye"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ajo.2009.02.012","article-title":"Refractory neovascular age-related macular degeneration secondary to polypoidal choroidal vasculopathy","volume":"148","author":"Cho","year":"2009","journal-title":"Am. J. Ophthalmol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"17013","DOI":"10.1038\/s41598-024-67671-w","article-title":"Sex differences in choroidal vessels using novel wide-field choroidal en-face images from optical coherence tomography","volume":"14","author":"Mihara","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1093\/cvr\/cvab096","article-title":"Clinical efficacy and safety of angiogenesis inhibitors: Sex differences and current challenges","volume":"118","author":"Cignarella","year":"2022","journal-title":"Cardiovasc. Res."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/5\/863\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T04:14:15Z","timestamp":1777695255000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/5\/863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":32,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["medicina62050863"],"URL":"https:\/\/doi.org\/10.3390\/medicina62050863","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]}}}